Kita H - Search Results

1

Time window for the contribution of the delta-opioid receptor to cardioprotection by ischemic preconditioning in the rat heart.

Tsuchida A, Miura T, Tanno M, Nozawa Y, Kita H, Shimamoto K. Tsuchida A, et al. Among authors: kita h. Cardiovasc Drugs Ther. 1998 Sep;12(4):365-73. doi: 10.1023/a:1007720801004. Cardiovasc Drugs Ther. 1998. PMID: 9825182

2

Infarct size limitation by bradykinin receptor activation is mediated by the mitochondrial but not by the sarcolemmal K(ATP) channel.

Kita H, Miura T, Miki T, Genda S, Tanno M, Fukuma T, Shimamoto K. Kita H, et al. Cardiovasc Drugs Ther. 2000 Oct;14(5):497-502. doi: 10.1023/a:1007837022300. Cardiovasc Drugs Ther. 2000. PMID: 11101197

3

Suppression of reperfusion arrhythmias by preconditioning is inhibited by an ATP-sensitive potassium channel blocker, 5-hydroxydecanoate, but not by protein kinase C blockers in the rat.

Kita H, Miura T, Tsuchida A, Hasegawa T, Shimamoto K. Kita H, et al. J Cardiovasc Pharmacol. 1998 Nov;32(5):791-7. doi: 10.1097/00005344-199811000-00016. J Cardiovasc Pharmacol. 1998. PMID: 9821854

4

Chronic treatment with an ACE inhibitor, temocapril, lowers the threshold for the infarct size-limiting effect of ischemic preconditioning.

Nozawa Y, Miura T, Tsuchida A, Kita H, Fukuma T, Shimamoto K. Nozawa Y, et al. Among authors: kita h. Cardiovasc Drugs Ther. 1999 Apr;13(2):151-7. doi: 10.1023/a:1007744428819. Cardiovasc Drugs Ther. 1999. PMID: 10372231

5

Roles of mitochondrial ATP-sensitive K channels and PKC in anti-infarct tolerance afforded by adenosine A1 receptor activation.

Miura T, Liu Y, Kita H, Ogawa T, Shimamoto K. Miura T, et al. Among authors: kita h. J Am Coll Cardiol. 2000 Jan;35(1):238-45. doi: 10.1016/s0735-1097(99)00493-3. J Am Coll Cardiol. 2000. PMID: 10636286 Free article.

6

[ACE inhibitors use in patients with acute coronary syndrome].

Miki T, Kita H, Miura T. Miki T, et al. Among authors: kita h. Nihon Rinsho. 1998 Oct;56(10):2601-6. Nihon Rinsho. 1998. PMID: 9796325 Review. Japanese.

7

Sulochrin inhibits eosinophil activation and chemotaxis.

Ohashi H, Motegi Y, Kita H, Gleich GJ, Miura T, Ishikawa M, Kawai H, Fukamachi H. Ohashi H, et al. Among authors: kita h. Inflamm Res. 1998 Oct;47(10):409-15. doi: 10.1007/s000110050352. Inflamm Res. 1998. PMID: 9831326

8

Eosinophil activation and function in health and disease.

Abu-Ghazaleh RI, Kita H, Gleich GJ. Abu-Ghazaleh RI, et al. Among authors: kita h. Immunol Ser. 1992;57:137-67. Immunol Ser. 1992. PMID: 1504137 Review.

9

Production of IL-8 and release of eosinophil-derived neurotoxin by normal peripheral blood eosinophils.

Nakajima H, Gleich GJ, Fukuda T, Makino S, Kita H. Nakajima H, et al. Among authors: kita h. Int Arch Allergy Immunol. 1997 Oct;114 Suppl 1:36-9. doi: 10.1159/000237715. Int Arch Allergy Immunol. 1997. PMID: 9363923

10

Sulochrin inhibits eosinophil degranulation.

Ohashi H, Ishikawa M, Ito J, Ueno A, Gleich GJ, Kita H, Kawai H, Fukamachi H. Ohashi H, et al. Among authors: kita h. J Antibiot (Tokyo). 1997 Nov;50(11):972-4. doi: 10.7164/antibiotics.50.972. J Antibiot (Tokyo). 1997. PMID: 9592574 Free article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

814 results

Search Page

Filters